Replies to post #50965 on EVIO Inc (EVIO)

[msg404]

Seeing as the corporate management of Waldrop and Glauser have an epic aversion to facts. I’d suggest you read the reviews left by almost EVERY employee “terrible/garbage/bad managaement/ not enough equipment to do the work right/ rushing samples thru pass/ blatant favoritism - just a smorgasbord salad of nasty negative plotyee reports now for months and months. Peppered in w one or two “managers” responding talking about how amazing it all is. So transparent and pathetic. Pretty much sums up the managaement team and the total lack of respect that employees and clients alike have for them.

Waldrop and Glauser turfed and replaces with a real, dynamic, energetic team working for shareholders and not their own limited petty selfish ego pursuits at the expense of shareholders - would see the share price 2x or 3x overnight. The staff would be doing cartwheels. The morale would improve dramatically. And the clients would be signing up like crazy.

As far as the status quo where tweedle and twaddle moron are in charge ploddingly their way from mess to catastrophe to mess and lurching and reacting with no plan and no support - more of the same. Teens and insolvency.

[msg404]

Readers should note $evio last issued a press release on the 17th of December, so there seems to be no official communication with shareholders on what would have been a material event. While the loss of Eugene and Bend would harm revenue, the reputation of the company has also likely suffered, so softer demand for its testing could likely have been experienced.

The primary pain point from EVIO Labs has been its failure to release its financial results. A daring feat that is only permissible by its over-the-counter listing. The company last released financials for the quarter ending June 30, 2018. A look at the company's investor relations states that the subsequent financials should be released, pending the completion of their audits, before the end of spring 2019. Which passed last week. Still nothing in communication

Charting EVIO Labs' last released financials highlights a declining revenue profile that has been combined with material quarter-over-quarter increases in negative net operating cash flow. Negative OCF as a percentage of revenue has also been rising. These financials are not good, a fact that is likely to have been exacerbated following the closure of EVIO Labs Eugene and EVIO Labs Bend.

EVIO Labs' employees were caught taking samples of marijuana sent to their respective labs for testing. Oregon's cannabis testing regulation specifies that samples sent to a lab for testing must be divided in half, with one half tested and one retained in the event of the need to retest. Employees of both labs were taking home samples after the 40 day retention period for the second half of the divided samples lapsed.

Readers should note the company last issued a press release on the 17th of December, so there seems to be no official communication with shareholders on what would have been a material event. While the loss of Eugene and Bend would harm revenue, the reputation of the company has also likely suffered, so softer demand for its testing could likely have been experienced.